RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)

The report reviews RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Almac Discovery Limited

ArQule, Inc.

AstraZeneca Plc

Bayer AG

Merck & Co., Inc.

Novartis AG

Rexahn Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) Overview 7

Therapeutics Development 8

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Products under Development by Stage of Development 8

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Products under Development by Therapy Area 9

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Products under Development by Indication 10

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Products under Development by Companies 14

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Products under Development by Universities/Institutes 18

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 22

Assessment by Molecule Type 24

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Companies Involved in Therapeutics Development 26

Almac Discovery Limited 26

ArQule, Inc. 27

AstraZeneca Plc 28

Bayer AG 29

Merck & Co., Inc. 30

Novartis AG 32

Rexahn Pharmaceuticals, Inc. 33

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Drug Profiles 34

ALM-301 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ARQ-092 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AZD-5363 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BAY-1001931 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BAY-1125976 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

MK-2206 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

MK-2206 + selumetinib sulfate - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

RX-0201 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

RX-0201N - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Inhibit AKT1 for Oncology - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Inhibit Akt1/2 for Oncology - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

trametinib dimethyl sulfoxide + uprosertib - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

uprosertib - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Dormant Projects 58

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC

2.7.11.1) - Featured News & Press Releases 61

Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting 61

Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting 62

Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data For Archexin-Nano At The 2016 American Association For Cancer Research Annual Meeting 63

Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma 63

Jan 28, 2016: ArQule Provides Update on ARQ 092 64

Jan 11, 2016: Rexahn Pharmaceuticals Archexin Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study 65

Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092 67

Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 67

Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium 68

Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics 70

Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology 70

Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference 71

May 13, 2015: Rexahn Announces Poster Presentation On RX-0201 at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting 72

Nov 13, 2014: ArQule Announces Data Presentations on ARQ 092 at 26th EORTC-NCI-AACR Symposium 72

Nov 11, 2014: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome 73

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Products under Development by Companies, H2 2016 (Contd..2) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Products under Investigation by Universities/Institutes, H2 2016 19

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by Almac Discovery Limited, H2 2016 26

Pipeline by ArQule, Inc., H2 2016 27

Pipeline by AstraZeneca Plc, H2 2016 28

Pipeline by Bayer AG, H2 2016 29

Pipeline by Merck & Co., Inc., H2 2016 30

Pipeline by Novartis AG, H2 2016 32

Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016 33

Dormant Projects, H2 2016 58

Dormant Projects (Contd..1), H2 2016 59

Dormant Projects (Contd..2), H2 2016 60

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports